AMAG Pharmaceuticals signs US licence agreement for Intrarosa
AMAG Pharmaceuticals | February 16, 2017
AMAG Pharmaceuticals has signed a licence agreement for US commercial rights to Intrarosa (prasterone). The locally administered, daily non-oestrogen product Intrarosa is used to treat moderate-to-severe dyspareunia (pain during intercourse), a common symptom of vulvar and vaginal atrophy (VVA) that occurs due to menopause.